Slide 1: Analyst / Investor Conference FY 2012 Results and Guidance FY 2013
Analyst / Investor Conference FY 2012 Results and Guidance FY 2013 February 14, 2013 03:00 p.m. CET Uwe Röhrhoff, CEO Rainer Beaujean, CFO
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Agenda
Agenda Review FY 2012 Uwe Röhrhoff, CEO Financial Overview FY 2012 Rainer Beaujean, CFO Guidance FY 2013 Uwe Röhrhoff, CEO 3
Slide 4: FY 2012: Strong set of results
FY 2012: Strong set of results Key Group figures in EUR m, EPS and dividend in EUR Revenues adjusted EBITDA FXN: + 9.8% adjusted EBITDA Margin + 11.4% + 8.8% 19.9% 19.4% adjusted EPS Dividend per share + 4.9% + 8.3% Proposed 4
Slide 5: Europe & North America most important, Emerging Markets gaining in significance
Europe & North America most important, Emerging Markets gaining in significance 2% Other 18% Emerging Markets1 34% Europe Revenues 2012 EUR 1,219m 23% Americas 23% Germany 1Emerging Markets (Definition according to IMS Health 2012): Brazil, Russia, India, China, Venezuela, Poland, Argentina, Turkey,
Slide 6: FY 2012 targets fully achieved
FY 2012 targets fully achieved Confirmed Guidance1 Actual results FY 2012 as of Oct. 4, 2012 FY 2012 Revenues + 9% to 10% at const. FX + 10.5% to 11.5% nominal2,3 + 9.8% at const. FX + 11.4% nominal2,3 Adj. EBITDA margin About 19.5% 19.4% Capex About EUR 120m EUR 118.9m 1 Includes stronger tha
Slide 7: Triveni acquisition in India: Strong base for growth
Triveni acquisition in India: Strong base for growth Acquisition of 75% stake in 12/2012 FY 2011/12 revenues approx. EUR 20m More than 300 employees Producer of plastic packaging bottles and closures Purchase price: Approximately EUR 55m, about 10X LTM EBITDA Triveni (New Delhi) 1 Head O
Slide 8: Agenda
Agenda Review FY 2012 Uwe Röhrhoff, CEO Financial Overview FY 2012 Rainer Beaujean, CFO Guidance FY 2013 Uwe Röhrhoff, CEO 8
Slide 9: FY 2012: Revenues by division
FY 2012: Revenues by division FY 2012 FY 2011 Change Change in % at EUR m EUR m in % const. FX1 Total Group 1,219.1 1,094.7 +11.4 +9.8 Plastic Systems 427.2 371.4 +15.0 +16.8 Moulded Glass 372.8 342.4 +8.9 +7.5 Tubular Glass 333.8 304.1 +9.8 +5.5 Life Science Research 99.6 91.8 +8.5 +0.6 1 Currency
Slide 10: FY 2012: Adjusted EBITDA and margin by division
FY 2012: Adjusted EBITDA1 and margin by division FY 2012 FY 2011 Margin Margin EUR m in % EUR m in % Total Group 236.5 19.4 217.3 19.9 Plastic Systems 92.8 21.7 87.1 23.4 Moulded Glass 81.8 22.0 76.8 22.4 Tubular Glass 67.8 20.3 62.4 20.5 Life Science Research 13.5 13.6 10.6 11.5 1 Earnings before i
Slide 11: FY 2012: Key balance sheet and cash flow figures
FY 2012: Key balance sheet and cash flow figures Nov. 30, 2012 Nov. 30, 2011 Change EUR m EUR m in % Total Assets 1,557.7 1,515.1 +2.8 Equity 580.1 552.2 +5.1 Equity ratio in % 37.2 36.4 Net Working Capital1 175.2 172.5 +1.6 in % of LTM revenues 14.4 15.8 Net Financial Debt2 366.5 364.6 +0.5 Adj. EB
Slide 12: Long-term financing structure with ample financial leeway
Long-term financing structure with ample financial leeway Comparison of debt/cash positions in EUR m Nov. 30, 2011 Nov. 30, 2012 Interest rate (due date): Bond 300.0 300.0 Fixed coupon at 5.0% (2018) Long-term bank debt 154.7 Interest rate hedged at 3.26% 135.8 Revolving bank debt 0.0 (2016) Local b
Slide 13: Agenda
Agenda Review FY 2012 Uwe Röhrhoff, CEO Financial Overview FY 2012 Rainer Beaujean, CFO Guidance FY 2013 Uwe Röhrhoff, CEO 13
Slide 14: FY 2013: Operational preview
FY 2013: Operational preview Revenues: Main growth drivers will be Plastic Systems and Tubular Glass Revenue expansion in Moulded Glass most likely softer than in FY 2012 Adjusted EBITDA margin: Tubular Glass expected to deliver a margin increase y-o-y Plastic Systems margin most likely
Slide 15: Guidance FY 2013
Guidance FY 2013 FY 2012 Guidance FY 2013 as reported Revenues EUR 1,219.1m1 + 5% to 6% at const. FX Approximately Adj. EBITDA margin 19.4% on 2012 level Approximately Capex EUR 118.9m on 2012 level 1 Average exchange rate for FY 2012: EUR 1.00 = USD 1.295 15
Slide 16: Financial Calendar
Financial Calendar April 10, 2013 Interim Report 1st Quarter 2013 April 18, 2013 Annual General Meeting July 10, 2013 Interim Report 2nd Quarter 2013 October 2, 2013 Interim Report 3rd Quarter 2013 16
Slide 17: Investor Relations & Creditor Relations contact details
Investor Relations & Creditor Relations contact details Phone +49 211 6181-257 Fax +49 211 6181-121 E-mail gerresheimer.ir@gerresheimer.com IR website www.gerresheimer.com/ir 17
Slide 18: Backup
GERRESHEIMER Backup
Slide 19: FY 2012 P&L Overview
FY 2012 P&L Overview FY 2012 FY 2011 Change EUR m EUR m in % Revenues 1,219.1 1,094.7 +11.4 Adjusted EBITDA1 236.5 217.3 +8.8 Restructuring expenses 0.0 0.1 -100.0 One-off income/expense -5.5 -6.9 +20.3 EBITDA 231.0 210.3 +9.8 Amortization of FV adjustments 18.0 20.6 -12.6 Depreciation and amortizat
Slide 20: Q4 2012 P&L Overview
Q4 2012 P&L Overview Q4 2012 Q4 2011 Change EUR m EUR m in % Revenues 324.9 288.4 +12.7 Adjusted EBITDA1 72.8 62.2 +17.0 Restructuring expenses 0.0 0.1 -100.0 One-off income/expense -0.8 -5.1 +84.3 EBITDA 72.0 57.0 +26.3 Amortization of FV adjustments 4.6 6.5 -29.2 Depreciation and amortization 20.2
Slide 21: Q4 2012: Revenues by division
Q4 2012: Revenues by division Q4 2012 Q4 2011 Change Change in % at EUR m EUR m in % const. FX1 Total Group 324.9 288.4 +12.7 +11.8 Plastic Systems 116.9 98.0 +19.3 +21.1 Moulded Glass 101.6 91.3 +11.4 +10.7 Tubular Glass 87.9 79.1 +11.1 +7.5 Life Science Research 22.2 23.6 -5.7 -10.6 1 Currency eff
Slide 22: Q4 2012: Adjusted EBITDA and margin by division
Q4 2012: Adjusted EBITDA1 and margin by division Q4 2012 Q4 2011 Margin Margin EUR m in % EUR m in % Total Group 72.8 22.4 62.2 21.6 Plastic Systems 28.1 24.0 25.9 26.5 Moulded Glass 24.7 24.3 22.6 24.8 Tubular Glass 21.0 23.9 16.1 20.4 Life Science Research 3.7 16.6 2.3 9.6 1 Earnings before income
Slide 23: Development of Working Capital
Development of Working Capital1 Nov. 30, 2012 Nov. 30, 2011 Nov. 30, 2010 EUR m EUR m EUR m Inventories 189.0 159.9 138.3 thereof prepayments made 12.4 13.9 6.1 Trade receivables 179.4 162.8 145.5 Trade payables 154.3 119.2 111.1 Payments received on account of orders 38.9 31.0 21.5 Net Working Capi
Slide 24: Development of Inventories
Development of Inventories Nov. 30, 2012 Nov. 30, 2011 Nov. 30, 2010 EUR m EUR m EUR m Raw materials, con- sumables and supplies 45.1 43.2 36.9 Work in progress 27.9 15.1 12.4 Finished goods and merchandise 103.6 87.7 82.9 Prepayments made 12.4 13.9 6.1 Inventories 189.0 159.9 138.3 24
Slide 25: 2012 Revenues: Regional split according to former definition (IMS health 2009)
2012 Revenues: Regional split according to former definition (IMS health 2009) 3% Other 14% Emerging Markets 36% Europe Revenues 2012 EUR 1,219m 24% Americas 23% Germany 25